Ferric Carboxymaltose (Ferinject)

Canada’s Drug Agency (CDA-AMC) recommends that Ferinject be reimbursed by public drug plans for the treatment of iron deficiency (ID) in adult patients with heart failure (HF) and New York Heart Association (NYHA) class II or III to improve exercise capacity if certain conditions are met. Ferinject should only be covered to treat adult patients with HF and NYHA class II or III and who have a left ventricular ejection fraction (LVEF) of 40% or less and a serum ferritin level of 300 mcg/L or lower with a transferrin saturation (TSAT) of less than 15%. Ferinject should only be reimbursed if prescribed by a cardiologist or clinician experienced in the management of chronic HF and if the cost of Ferinject is reduced.